Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment (BATMAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00122356
Recruitment Status : Completed
First Posted : July 22, 2005
Last Update Posted : March 13, 2013
Information provided by (Responsible Party):
Barwon Health

Brief Summary:
The purpose of this study is to evaluate the use of an oral bisphosphonate (alendronate) in preventing bone loss in postmenopausal women with early breast cancer who are receiving anastrozole therapy, and to determine how long alendronate treatment is needed.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Alendronate sodium Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 303 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Maintaining Skeletal Health in Postmenopausal Women With Surgically Resected Stage I-IIIa Hormone-receptor Positive Breast Cancer Who Are Receiving Anastrozole, Through the Use of Alendronate as Determined by the Osteoporosis Australia Bone Maintenance Algorithm
Study Start Date : September 2005
Actual Primary Completion Date : February 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Anastrozole and alendronate
Patients will receive anastrozole for 5 years and alendronate for 3 years or anastrozole and alendronate treatment for 5 years.
Drug: Alendronate sodium
70mg tablets, once weekly
Other Names:
  • Fosamax
  • Alendro
  • Adronat

Primary Outcome Measures :
  1. Changes in lumbar vertebra and femoral neck bone mineral density (BMD) T-score after 5 years of anastrozole treatment [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Percent change in the lumbar vertebra (L2 to L4) and femoral neck BMD [ Time Frame: 12 monthly intervals ]
  2. Biochemical markers of bone turnover (N-telopeptide and bone-specific alkaline phosphatase) and BMD [ Time Frame: 6 months after registration and/or 6 months after commencing alendronate ]
  3. Evaluate the Osteoporosis Australia strategy for bone protection for this patient group [ Time Frame: 5 years ]
  4. Evaluate the clinical fracture incidence cumulative over 5 years [ Time Frame: 5 years ]
  5. Perform an economic analysis of the cost of monitoring and intervention [ Time Frame: 5 years ]
  6. Evaluate the time to disease recurrence/relapse in women treated with anastrozole as adjuvant therapy [ Time Frame: 5 years ]
  7. Evaluate the effects of anastrozole on serum lipid parameters following 6 months therapy [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal
  • Adequately diagnosed and treated Stage I-IIIa early breast cancer
  • Oestrogen receptor and/or progesterone receptor positive breast cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
  • Hormone replacement therapy (HRT) must be discontinued at least 2 weeks prior to registration
  • Any prior tamoxifen taken for a total of 8 weeks or less
  • Any prior anastrozole taken for a total of 4 weeks or less
  • Anastrozole is clinically indicated to be the best adjuvant strategy
  • Signed written informed consent

Exclusion Criteria:

  • Clinical or radiological evidence of distant spread of disease
  • Prior treatment with bisphosphonates within the past 12 months
  • Prior treatment with continuous systemic corticosteroids within the past 12 months
  • Prior use of parathyroid hormone for more than 1 week
  • Prior use of systemic sodium fluoride for > 3 months during the past 2 years
  • Currently treated with any drugs known to affect the skeleton
  • Abnormal renal function (serum creatinine greater than or equal to 265.2 mmol/L)
  • History of diseases with influence on bone metabolism. Patients with lactose intolerance are also excluded
  • Delayed oesophageal emptying such as stricture or achalasia
  • Hypersensitivity to alendronate or anastrozole
  • Previous or concomitant malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix
  • AST/SGOT and/or ALT/SGPT > 3 x ULN in combination with other laboratory and clinical abnormalities indicating liver insufficiency
  • Fracture due to minimal trauma, demonstrated radiologically

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00122356

Layout table for location information
Australia, New South Wales
Sydney South West Area Health Service
Sydney, New South Wales, Australia, 2050
Tweed Hospital
Tweed Heads, New South Wales, Australia, 2485
Australia, Victoria
Box Hill Hospital
Box Hill, Victoria, Australia, 3128
Maroondah Breast Clinic
East Ringwood, Victoria, Australia, 3135
St Vincent's Health
Fitzroy, Victoria, Australia, 3065
Barwon Health
Geelong, Victoria, Australia, 3220
St John of God Healthcare
Geelong, Victoria, Australia, 3220
South West Healthcare
Warrnambool, Victoria, Australia, 3280
Sponsors and Collaborators
Barwon Health
Layout table for investigator information
Principal Investigator: Karen White Barwon Health
Layout table for additonal information
Responsible Party: Barwon Health Identifier: NCT00122356    
Other Study ID Numbers: ALCC 04.02
First Posted: July 22, 2005    Key Record Dates
Last Update Posted: March 13, 2013
Last Verified: March 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs